Orlistat powder (96829-58-2)

Orlistat powder (96829-58-2) video

 

Orlistat powder (96829-58-2) Base Information

Name	Orlistat
CAS	96829-58-2
Purity	98%
Chemical name	Orlistat
Synonyms	Tetrahydrolipstatin Xenical Alli
Molecular Formula	C29H53NO5
Molecular Weight	495.7 g/mol
Melting Point	/
InChI Key	AHLBNYSZXLDEJQ-FWEHEUNISA-N
Form	Solid
Appearance	White powder
Half Life	1-2 hours
Solubility	water solubility：Practically insoluble
Storage Condition	Store in a sealed airtight container, keep the air out, protected from heat, light and humidity.
Application	Use to loss weight or have weight-related medical problems
Testing Document	Available

 

Orlistat powder (96829-58-2) General Description

Orlistat powder is a drug designed to treat obesity. It is marketed as a prescription drug under the trade name Xenical by Roche in most countries, and is sold over-the-counter as Alli by GlaxoSmithKline in the United Kingdom and the United States.Its primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet.

Orlistat powder is the saturated derivative of lipstatin, a potent natural inhibitor of pancreatic lipases isolated from the bacterium Streptomyces toxytricini.However, due to its relative simplicity and stability, orlistat powder was chosen over lipstatin for development as an anti-obesity drug.

 

Orlistat powder (96829-58-2) History

Orlistat powder is used to aid in weight loss, or to help reduce the risk of regaining weight already lost. This medicine must be used together with a reduced-calorie diet. Orlistat is for use only in adults.

 

Orlistat powder (96829-58-2) Mechanism Of Action

Orlistat powder is a reversible inhibitor of lipases. It exerts its therapeutic activity in the lumen of the stomach and small intestine by forming a covalent bond with the active serine residue site of gastric and pancreatic lipases. The inactivated enzymes are thus unavailable to hydrolyze dietary fat in the form of triglycerides into absorbable free fatty acids and monoglycerides. As undigested triglycerides are not absorbed, the resulting caloric deficit may have a positive effect on weight control.

 

Orlistat powder (96829-58-2) Application

Orlistat powder is used with a doctor-approved exercise, behavior change, and reduced-calorie diet program to help you lose weight. It is used by certain overweight people, such as those who are obese or have weight-related medical problems. Taking orlistat can also help keep you from gaining back weight you have lost. Losing weight and keeping it off can lessen the many health risks that come with obesity, including heart disease, diabetes, high blood pressure, and a shorter life.

 

Orlistat powder (96829-58-2) More research

People may will ask “Dose Orlistat Really Work?”.

If used together with additional weight loss tactics, Orlistat has been shown to be effective at aiding weight loss.

One study found that people who took Orlistat and kept to a low-calorie diet lost on average 1.25 stone (8.1kg) a year, which was 6lb (2.8kg) more than those who did not take Orlistat during the same time period.

Another study found that 743 obese patients taking Orlistat for weight loss had lost on average 10.3kg of weight after one year. This is in contrast to the 6.1kg patients not taking Orlistat lost.

Other studies have also found that people following this course of treatment could lose up to 10% of their body weight in a year.

As with many medications, there are some side effects of Orlistat. The most common recorded Orlistat side effects of taking Orlistat is experiencing headaches.

 

Orlistat powder (96829-58-2) Reference

[1] Orlistat 120mg capsule blister pack”. TGA. 11 April 2000. Retrieved 18 April 2018.

[2]J. A. Menendez; L. Vellon; R. Lupu (2005). “Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene”. Annals of Oncology. 16 (8): 1253–1267. doi:10.1093/annonc/mdi239. PMID 15870086.

[3]”FDA Approves Orlistat for Over-the-Counter Use” (Press release). U.S. Food and Drug Administration (FDA). 7 February 2007. Retrieved 7 February 2007.

[4]Saul, Stephanie (7 February 2007). “Weight-Loss Drug to Be Sold Over the Counter”. The New York Times. Retrieved 10 February 2007.